 | | Vol. 14.03 – 27 January, 2022 |
| |
|
|
| Scientists determined whether human chronic villi-mesenchymal stromal cells (hCV-MSCs) were ciliated and whether altered ciliation was responsible for defective hCV-MSCs in preeclamptic placentas, as the primary cilium was a hub for signal transduction, which was important for various cellular activities.
[BMC Medicine] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors cross-compared transcriptomic and proteomic data and selected 26 candidate genes with the same expression trends in both omics analyses.
[Stem Cell Reviews and Reports] |
|
|
|
| A novel protocol was developed to isolate and culture decidual natural killer cells cells from fresh, term placentas and complete hydatidiform moles.
[Journal of Reproductive Immunology] |
|
|
|
| Researchers examined the impact of the reduced uterine perfusion pressure rat model of preeclampsia on the maternal cardiovascular system, placental and fetal heart metabolism.
[Scientific Reports] |
|
|
|
| Trisomy 16 is the most common aneuploidy in first-trimester miscarriages. Scientists identified changes in DNA methylation in chorionic villi of miscarriages with trisomy 16.
[Scientific Reports] |
|
|
|
| Scientists explored the effect of abnormally expressed long non-coding RNA ZEB2-AS1 on the occurrence of recurrent spontaneous abortion.
[Reproductive Sciences] |
|
|
|
| Researchers determined whether metabolites from a retrospective collection of banked cord blood specimens could accurately estimate gestational age and validated these findings in cord blood samples from Busia, Uganda.
[Journal of Perinatology] |
|
|
|
|
| The authors review currently available information on lead (Pb)-mediated alterations in the fetal epigenome is summarized.
[Journal of Applied Toxicology] |
|
|
|
|
| Celularity Inc. announced the US FDA has granted Fast Track Designation for its genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-101, which is being developed in combination with standard chemotherapy, trastuzumab and pembrolizumab in patients in first-line locally advanced unresectable or metastatic HER2/neu positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
[Celularity, Inc.] |
|
|
|
|
| March 19 – 23, 2022
Prague, Czech Republic & Online |
|
|
|
|
|
| | Penn State College of Medicine – Hershey, Pennsylvania, United States |
|
|
|
| Albert Einstein College of Medicine – Bronx, New York, United States |
|
|
|
| Harvard Medical School – Boston, Massachusetts, United States |
|
|
|
| Fox Chase Cancer Center, Temple University – Philadelphia, Pennsylvania, United States |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
